

Pharmacy Program Updates: Upcoming Pharmacy Changes Effective July 1, 2015

STANDARD DRUG LIST (FORMULARY) CHANGES

Based on the availability of new prescription medications and the Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some revisions will be made to the BCBSIL standard drug list effective July 1, 2015.

Brand Medications Added to the Drug List, Effective July 1, 2015

Preferred Brand ¹	Drug Class/Condition Used For
Stelara	Autoimmune
Simponi	Autoimmune
Eliquis	Anticoagulant
Toujeo	Diabetes
Ibrance	Cancer
Incruse Ellipta	COPD

Brand Medications Moved to a Higher Out-of-Pocket Payment Level, Effective July 1, 2015

Non-Preferred Brand ^{1,2}	Condition Used For	Generic Preferred Alternative(s) ²	Preferred Brand Alternative(s) ^{1,2}
Olysio	Hepatitis C	N/A	Harvoni
Mestinon	Neuromuscular Disorders	pyridostigmine	N/A
Mestinon Timespan	Neuromuscular Disorders	pyridostigmine	N/A

DISPENSING LIMIT CHANGES

The BCBSIL standard prescription drug benefit program includes coverage limits on certain medications and drug categories. Dispensing limits are based on U.S. Food and Drug Administration (FDA) approved dosage regimens and product labeling.

Effective July 1, 2015, dispensing limits were added for the following drugs:

Drug Class and Medication¹	Product Strength(s)	Dispensing Limit
Afrezza		
Afrezza (insulin human) inhalation powder	4 units/cartridge	19 packs per 30 days (1 pack = 90 cartridges)
Afrezza (insulin human) inhalation powder	4 units and 8 units/cartridge	14 packs per 30 days (1 pack = 60 x 4 unit cartridges, 30 x 8 unit cartridges)
Afrezza (insulin human) inhalation powder	4 units and 8 units/cartridge	12 packs per 30 days (1 pack = 30 x 4 unit cartridges, 60 x 8 unit cartridges)
Fibrates		
Antara (fenofibrate)	30 mg, 43 mg micronized capsules	60 capsules per 30 days
Antara (fenofibrate)	90 mg, 130 mg micronized capsules	30 capsules per 30 days
Fenoglide (fenofibrate)	40 mg tablets	60 tablets per 30 days
Fenoglide (fenofibrate)	120 mg tablets	30 tablets per 30 days
Fibricor (fenofibric acid)	35 mg tablets	60 tablets per 30 days
Fibricor (fenofibric acid)	105 mg tablets	30 tablets per 30 days
Lipofen (fenofibrate)	50 mg capsules	60 capsules per 30 days
Lipofen (fenofibrate)	150 mg capsules	30 capsules per 30 days
Lofibra (fenofibrate)	54 mg tablets	60 tablets per 30 days
Lofibra (fenofibrate)	160 mg tablets	30 tablets per 30 days
Lofibra (fenofibrate)	67 mg, 134 mg, 200 mg micronized capsules	30 capsules per 30 days
Tricor (fenofibrate)	48 mg tablets	60 tablets per 30 days
Tricor (fenofibrate)	145 mg tablets	30 tablets per 30 days
Triglide (fenofibrate)	50 mg tablets	60 tablets per 30 days
Triglide (fenofibrate)	160 mg tablets	30 tablets per 30 days
Trilipix (fenofibric acid)	45 mg delayed-release tablets	60 tablets per 30 days
Trilipix (fenofibric acid)	135 mg delayed-release tablets	30 tablets per 30 days
Lopid (gemfibrozil)	600 mg tablets	60 tablets per 30 days
Hetlioz		
Hetlioz (tasimelteon)	20 mg capsule	30 capsules per 30 days

Korlym		
Korlym (mifepristone)	300 mg tablet	60 tablets per 30 days
Ophthalmic Prostaglandins		
Unoprostone	All strengths	5 mL per 30 days
Topical Cancer Treatment		
Picato (ingenol mebutate)	0.015% gel	3 tubes per 90 days
Picato (ingenol mebutate)	0.05% gel	2 tubes per 90 days

UTILIZATION MANAGEMENT PROGRAM CHANGES

Effective July 1, 2015, the Idiopathic Thrombocytopenic Purpura (ITP) specialty prior authorization (PA) program changed its name to: Thrombopoietin Receptor Agonists. The Familial Hypercholesterolemia specialty PA program also changed its name to: Hypercholesterolemia. All targeted medications and program criteria for both programs remain the same.

Additionally, several drug categories will be added to the BCBSIL Prior Authorization (PA) and Step Therapy (ST) programs for standard pharmacy benefit plans upon renewal.

Drug Categories Added to the Pharmacy PA Program, Effective July 1, 2015

Drug Category	Targeted Medications ¹
Afrezza	Afrezza
Hetlioz	Hetlioz
Korlym	Korlym
Myalept	Myalept

Drug Categories Added to the Pharmacy ST Program, Effective July 1, 2015

Drug Category	Targeted Medications ¹
Atopic Dermatitis	Elidel, Protopic
Fibrate	Antara, Fenoglide, Fibracor, Lipofen, Lofibra, Tricor, Triglide, Trilipix
Ophthalmic Prostaglandins/Glaucoma	Lumigen, Rescula, Travatan Z, Travaprost, Xalatan, Zioptan

Targeted mailings were sent to members affected by standard drug list deletions, dispensing limit and prior authorization program changes per our usual process of member notification prior to implementation. For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our website at bcbsil.com/provider.

¹Third party brand names are the property of their respective owners

²These lists are not all inclusive. Other medications may be available in this drug class.

Prime Therapeutics LLC is a pharmacy benefit management company. BCBSIL contracts with Prime to provide pharmacy benefit management, prescription home delivery and specialty pharmacy services. BCBSIL, as well as several other independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.